Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PRKACA | P17612 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30189823 | 1.00 | HSD17B10 (0.49) | HSD17B10HTTALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL5309925 | 0.81 | HSD17B10 (0.52) | HSD17B10HTTALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL28383665 | 0.81 | GAA (0.35) | HSD17B10ALDH1A1SMN1; SMN2TP53CYP3A4 | |
| SCHEMBL30189809 | 0.79 | LMNA (0.33) | HSD17B10CYP3A4LMNAADORA3 | |
| SCHEMBL19783530 | 0.79 | LMNA (0.33) | HSD17B10CYP3A4LMNAADORA3 | |
| SCHEMBL25291816 | 0.78 | ALDH1A1 (0.41) | HSD17B10HTTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL19782827 | 0.78 | HTT (0.53) | HSD17B10HTTALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL22392512 | 0.77 | CYP3A4 (0.45) | HSD17B10ALDH1A1SMN1; SMN2CYP3A4LMNA | |
| SCHEMBL30421066 | 0.77 | CYP3A4 (0.45) | HSD17B10ALDH1A1SMN1; SMN2CYP3A4LMNA | |
| Bromide SCHEMBL28941281 | 0.76 | HTT (0.51) | HSD17B10HTTALDH1A1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111630051-B | Olefin spiro compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-12-26 | — | — | CN | disclosed |
| EP-3704112-B1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3704112-B1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-111511731-B | Olefin compounds as modulators of the farnesol X receptor | 百时美施贵宝公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-3704106-B1 | ALKENE COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11286252-B2 | Alkene spirocyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-03-29 | — | — | US | disclosed |
| US-11168079-B2 | Alkene compounds as farnesoid x receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-09 | — | — | US | disclosed |
| US-11168079-B2 | Alkene compounds as farnesoid x receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210179599-A1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-20200283430-A1 | ALKENE COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200283430-A1 | ALKENE COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-10 | — | — | US | disclosed |
| CN-111630051-A | Spirocyclic compounds of alkenes as farnesoid X receptor modulators | 百时美施贵宝公司 | 2020-09-04 | — | — | CN | disclosed |
| CN-111511731-A | Olefin compounds as farnesoid X receptor modulators | 百时美施贵宝公司 | 2020-08-07 | — | — | CN | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, PF4 | HSD17B10 2283/4885HTT 2480/4885ALDH1A1 1618/4885 |
| US-11286252-B2 | Alkene spirocyclic compounds as farnesoid X receptor modulators | NR1H2, NR1H4, NR1H3 | HSD17B10 363/4885HTT 4141/4885ALDH1A1 1437/4885 |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | HSD17B10 2146/4885HTT 2559/4885ALDH1A1 1598/4885 |
| US-20210179599-A1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | NR1H2, NR1H4, NR1H3 | HSD17B10 363/4885HTT 4141/4885ALDH1A1 1437/4885 |
| US-11168079-B2 | Alkene compounds as farnesoid x receptor modulators | FXR1, NR1H2, NR1H4 | HSD17B10 358/4885HTT 4422/4885ALDH1A1 2224/4885 |
| US-20200283430-A1 | ALKENE COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H2, NR1H4 | HSD17B10 358/4885HTT 4422/4885ALDH1A1 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.